TG Therapeutics, Inc. $TGTX Shares Bought by Police & Firemen s Retirement System of New Jersey

Police & Firemen s Retirement System of New Jersey grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 10.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 32,914 shares of the biopharmaceutical company’s stock after purchasing an additional 3,174 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in TG Therapeutics were worth $1,185,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in TGTX. Geode Capital Management LLC raised its holdings in shares of TG Therapeutics by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock worth $126,033,000 after purchasing an additional 207,890 shares in the last quarter. PNC Financial Services Group Inc. grew its position in TG Therapeutics by 7.5% in the second quarter. PNC Financial Services Group Inc. now owns 9,696 shares of the biopharmaceutical company’s stock worth $349,000 after buying an additional 677 shares during the last quarter. SBI Securities Co. Ltd. grew its position in TG Therapeutics by 300.2% in the second quarter. SBI Securities Co. Ltd. now owns 2,385 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 1,789 shares during the last quarter. Profund Advisors LLC increased its holdings in shares of TG Therapeutics by 4.9% in the second quarter. Profund Advisors LLC now owns 44,442 shares of the biopharmaceutical company’s stock valued at $1,599,000 after buying an additional 2,057 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of TG Therapeutics in the second quarter valued at $195,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. B. Riley raised TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday. HC Wainwright began coverage on TG Therapeutics in a report on Monday, October 6th. They set a “buy” rating and a $60.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

Insider Activity at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director directly owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 10.64% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $31.95 on Friday. The company has a market capitalization of $5.07 billion, a price-to-earnings ratio of 86.35 and a beta of 1.95. TG Therapeutics, Inc. has a 1-year low of $25.28 and a 1-year high of $46.48. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. The stock’s fifty day simple moving average is $33.78 and its 200-day simple moving average is $33.95.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. During the same period last year, the company posted $0.02 EPS. The business’s quarterly revenue was up 92.7% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.